

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2696)**

## **VOLUNTARY ANNOUNCEMENT**

### **INCLUSION OF FUTUONING (FOVINACICLIB CITRATE CAPSULES) IN THE NATIONAL REIMBURSEMENT DRUG LIST**

#### **A. INTRODUCTION**

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, FUTUONING (Fovinaciclib Citrate Capsules) (“**FUTUONING**”) has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (Year 2025) (the “**NRDL**”), for the indication of in combination with Fulvestrant for the treatment of adult patients with hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER2) negative recurrent or metastatic breast cancer, who have experienced disease progression after prior endocrine therapy. The new edition of the NRDL will officially come into effect on 1 January 2026.

#### **B. ABOUT FUTUONING**

FUTUONING is an in-licensed innovative CDK4/6 small molecule inhibitor of the Company. In May 2025, FUTUONING was approved for marketing in mainland China. The first indication being approved is in combination with Fulvestrant for the treatment of adult patients with hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER2) negative recurrent or metastatic breast cancer, who have experienced disease progression after prior endocrine therapy. In September 2025, another indication of FUTUONING, i.e. in combination with an aromatase inhibitor as initial endocrine therapy for the treatment of adult patients with hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER2) negative locally advanced or metastatic breast cancer, was approved in mainland China.

## C. IMPACTS ON THE COMPANY

The inclusion of FUTUONING in the NRDL reflects the recognition of the National Healthcare Security Administration on its clinical values, benefits to patients and innovation level, etc. It will enhance the accessibility of patients with HR positive and HER2 negative breast cancer, and is beneficial for the marketing and sales layout of FUTUONING.

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

Hong Kong, 7 December 2025

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.*